ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals Inc.

In a report released yesterday, from Oppenheimer maintained a Buy rating on ARS Pharmaceuticals, with a price target of $35.00. The company’s share...

ARS Pharmaceuticals (SPRY) Gets a Buy from Oppenheimer

Ars Pharmaceuticals, Inc. (($SPRY)) announced an update on their ongoing clinical study. Study Overview: Ars Pharmaceuticals, Inc. is conducting a ...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SPRY	$7.59	+12.78%	3.90M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SPRY	$7.59	+12.8%	3.90M
3
4
5
6

SPRY

SPRY

Dividend Overview

Get ARS Pharmaceuticals Inc. Data in Excel

Get ARS Pharmaceuticals Inc. Data in Excel